# TENOTRYL- enrofloxacin solution Virbac AH, Inc.

-----

Tenotryl™ (enrofloxacin) 100 mg/mL Antimicrobial Injectable Solution

For Subcutaneous Use In Beef Cattle And Non-Lactating Dairy Cattle

For Intramuscular Or Subcutaneous Use In Swine

Not For Use In Female Dairy Cattle 20 Months Of Age Or OlderOr In Calves To Be Processed For Veal

### CAUTION:

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Federal (USA) law prohibits the extra-label use of this drug in food-producing animals. To assure responsible antimicrobial drug use, enrofloxacin should only be used as a second-line drug for colibacillosis in swinefollowing consideration of other therapeutic options.

# **PRODUCT DESCRIPTION:**

Tenotryl<sup>™</sup> is a sterile, ready-to-use injectable antimicrobial solution that contains enrofloxacin, a broad-spectrum fluoroquinolone antimicrobial agent.Each mL of Tenotryl<sup>™</sup> contains 100 mg of enrofloxacin. Excipients are L-arginine base 200 mg, nbutyl alcohol 30 mg, benzyl alcohol (as a preservative) 20 mg and water for injection q.s.

# CHEMICAL NOMENCLATURE AND STRUCTURE:

1-cyclopropyl-7-(4-ethyl-1-piperaz-inyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.



### INDICATIONS:

**Cattle - Single-Dose Therapy:** Tenotryl<sup>™</sup> is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida, Histophilus somni* and *Mycoplasma bovis* in beef and non-lactating dairy cattle; and for the control of BRD in beef and non-lactating dairy cattle at high risk of developing BRD associated with *M. haemolytica, P. multocida, H. somni and M. bovis.* 

Cattle - Multiple-Day Therapy: Tenotryl<sup>™</sup> is indicated for the treatment of bovine

respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida* and *Histophilus somni* in beef and non-lactating dairy cattle.

**Swine:** Tenotryl<sup>™</sup> is indicated for the treatment and controlof swine respiratory disease (SRD) associated with *Actinobacilluspleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, Streptococcus suis, Bordetella bronchiseptica* and *Mycoplasma hyopneumoniae.* Tenotryl<sup>™</sup> is indicated for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with *Escherichia coli* has been diagnosed.

# DOSAGE AND ADMINISTRATION:

Tenotryl<sup>™</sup> provides flexible dosages and durations of therapy. Tenotryl<sup>™</sup> may be administered as a single dose for one day for treatment and control of BRD (cattle), for treatment and control of SRD or for control of colibacillosis (swine), or for multiple days for BRD treatment (cattle). Selection of the appropriate dose and duration of therapy for BRD treatment in cattle should be based on an assessment of the severity of the disease, pathogen susceptibility and clinical response.

#### Cattle:

**Single-Dose Therapy (BRD Treatment):** Administer, by subcutaneous injection, a single dose of 7.5-12.5 mg/kg of body weight (3.4-5.7 mL/100 lb).

**Multiple-Day Therapy (BRD Treatment):** Administer daily, a subcutaneous dose of 2.5-5 mg/kg of body weight (1.1-2.3 mL/100 lb).Treatment should be repeated at 24-hour intervals for three days. Additional treatments may be given on Days 4 and 5 to animals that have shown clinical improvement but not total recovery.

**Single-Dose Therapy (BRD Control):** Administer, by subcutaneous injection, a single dose of 7.5 mg/kg of body weight (3.4 mL/100 lb).Examples of conditions that may contribute to calves being at high risk of developing BRD include, but are not limited to, the following:

- Transportation with animals from two or more farm origins.
- An extended transport time with few to no rest stops.
- An environmental temperature change of  $\geq$  30°F during transportation.
- A  $\geq$  30°F range in temperature fluctuation within a 24-hour period.
- Exposure to wet or cold weather conditions.
- Excessive shrink (more than would be expected with a normal load of cattle).
- Stressful arrival processing procedures (e.g., castration or dehorning).
- Exposure within the prior 72 hours to animals showing clinical signs of BRD.

Administered dose volume should not exceed 20 mL per injection site.

	Treat	Control	
Weight (lb)	Single-Dose Therapy 7.5 - 12.5 mg/kg Dose Volume (mL)	Multiple-Day Therapy 2.5 - 5.0 mg/kg Dose Volume (mL)	Single-Dose Therapy 7.5 mg/kg Dose Volume (mL)
100	3.5 - 5.5	1.5 - 2.0	3.5
200	7.0 - 11.0	2.5 - 4.5	7.0
300	10.5 - 17.0	3.5 - 6.5	10.5
400	14.0 - 22.5	4.5 - 9.0	14.0
500	17.0 - 28.5	5.5 - 11.5	17.0
600	20.5 - 34.0	7.0 - 13.5	20.5
700	24.0 - 39.5	8.0 - 16.0	24.0
800	27.5 - 45.5	9.0 - 18.0	27.5
900	31.0 - 51.0	10.0 - 20.5	31.0
1000	34.0 - 57.0	11.0 - 23.0	34.0
1100	37.5 - 62.5	12.5 - 25.0	37.5

Table 1 – TenotryI<sup>™</sup> Dose and Treatment Schedule for Cattle\*

\*Dose volumes have been rounded to the nearest 0.5 mL within the dose range.

#### Swine:

Administer, either by intramuscular or subcutaneous (behind the ear) injection, a single dose of 7.5 mg/kg of body weight (3.4 mL/100 lb). Administered dose volume should not exceed 5 mL per injection site. For the control of colibacillosis, administration should be initiated within the first 60 days post-weaning when clinical signs are presenting at least 2% of the animals in the group. If no improvement is noted within 48 hours, the diagnosis should be reevaluated.

Weight (lb)	Dose Volume (mL)
15	0.5
30	1.0
50	1.7
100	3.4
150	5.1
200	6.8
250	8.5

Table 2 - Tenotryl<sup>™</sup> Dose Schedule for Swine

**Dilution of Tenotryl:** Tenotryl<sup>™</sup> may be diluted with sterile water prior to injection. The diluted product should be used within 24 hours. Store diluted solution in amber glass bottles between 5°C - 40°C (41°F – 104°F), excursions are not permitted.

Swine Weight	mL of Tenotryl™	mL of sterile water	Number of doses
10 lb	34 mL	66 mL	100
15 lb	51 mL	49 mL	100
20 lb	68 mL	32 mL	100
25 lb	85 mL	15 mL	100

\*For 1 mL dose volume from diluted solution

Use within 30 days of first puncture and puncture a maximum of 30times with a 16gauge needle or smaller, or 4 times with a draw-off spike 4.75 mm or smaller. Any product remaining beyond these parameters should be discarded.

#### **RESIDUE WARNINGS:**

Cattle: Animals intended for human consumption must not be slaughtered within 28 days from the last treatment. This product is not approved for female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. Swine: Animals intended for human consumption must not be slaughtered within 5 days of receiving a single-injection dose.

#### HUMAN WARNINGS:

**Not for use in humans. Keep out of reach of children.** Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposures. Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk ofuser photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight. To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet, contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

#### **PRECAUTIONS:**

The effects of enrofloxacin on cattle or swine reproductive performance, pregnancy and lactation have not been adequately determined. The long-term effects on articular joint cartilage have not been determined in pigs above market weight.

Subcutaneous injection in cattle and swine, or intramuscular injection in swine, can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

Enrofloxacin injectable solution contains different excipients than other enrofloxacin products. The safety and efficacy of this formulation in species other than cattle and swine have not been determined.

Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures. Quinolone-class drugs have been shown to produce erosions of cartilage of weightbearing joints and other signs of arthropathy in immature animals of various species. See Animal Safety section for additional information.

### **ADVERSE REACTIONS:**

No adverse reactions were observed during clinical trials.For additional information about adverse drug experience reportingfor animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae.

#### **MICROBIOLOGY:**

Enrofloxacin is bactericidal and exerts its antibacterial effect by inhibiting bacterial DNA gyrase (a type II topoisomerase) therebypreventing DNA supercoiling and replication which leads to cell death.<sup>1</sup> Enrofloxacin is active against Gram-negative and Grampositive bacteria.

## **EFFECTIVENESS:**

Cattle: A total of 845 calves with naturally-occurring BRD were treated with enrofloxacin in eight field trials located in five cattle-feeding states. Response to treatment was compared to non-treated controls. Single-dose and multiple-day therapy regimens were evaluated. BRD and mortality were significantly reduced in enrofloxacintreated calves. No adverse reactions were reported in treated animals. The effectiveness of enrofloxacin for the control of respiratory disease in cattle at high risk of developing BRD was evaluated in a six-location study in the U.S. and Canada. A total of 1,150 crossbred beef calves at high risk of developing BRD were enrolled in the study. Enrofloxacin (7.5 mg/kg BW) or an equivalent volume of sterile saline was administered as a single subcutaneous injection within two days after arrival. Cattle were observed daily for clinical signs of BRD and were evaluated for success on Day 14 post-treatment. Treatment success in the enrofloxacin group (497/573, 87.83%) was significantly higher (P = 0.0013) than success in the saline control group (455/571, 80.92%). In addition, there were more treatment successes (n = 13) than failures (n = 3) in the group of animals positive for *M. bovis* on Day 0 that were treated with enrofloxacin. No productrelated adverse reactionswere reported.

**Swine:** A total of 590 pigs were treated with enrofloxacin or saline in two separate natural infection SRD field trials. For the treatment of SRD, the success rate of enrofloxacin-treated pigs that were defined as "sick and febrile" (increased respiratory rate, labored or dyspneic breathing, depressed attitude and a rectal temperature  $\geq$  104°F) was statistically significantly greater than the success rate of saline-treated "sick and febrile" pigs. For the control of SRD, mean rectal temperature, mortality (one trial) and morbidity were statistically significantly lower for enrofloxacin-treated pigs in pens containing a percentage of "sick and febrile" pigs compared to saline-treated pigs.

The effectiveness of enrofloxacin administered as a single SC dose of 7.5 mg/kg BW for the treatment and control of SRD associated with M. hyopneumoniae was demonstrated using an induced infection model study and three single-site natural infection field studies. In the model study, 72 healthy pigs were challenged with a representative M. hyopneumoniae isolate and treated with enrofloxacin or saline. A statistically significant (P < 0.0001) decrease in the mean total lung lesion score was observed in the enrofloxacin-treated group (4%) compared with the saline-treated group (27%) at 10 days post-treatment. In two field studies evaluating effectiveness for treatment of SRD, a total of 300 pigs with clinical signs of SRD (moderate depression, moderately increased respiratory rate, and a rectal temperature of  $\geq 104^{\circ}$ F) were enrolled and treated with enrofloxacin or saline. At 7 days post-treatment, the cure rate was statistically significantly higher at each site (P < 0.0001) in the enrofloxacin-treated groups (61.3%) and 92%) compared with the saline-treated groups (26.7% and 33.3%). In one field study evaluating effectiveness for control of SRD, a group of 400 pigs in which > 15%had clinical signs of SRD (moderate depression score, moderately increased respiratory rate, and a rectal temperature of  $\geq$  104°F) was enrolled and treated with enrofloxacin or

saline. At 7 days post-treatment, the cure rate was statistically significantly higher (P < 0.0002) in the enrofloxacin-treated group (70.0%) compared with the saline-treated group (48.5%). In addition to *M. hyopneumoniae*, *B. bronchiseptica* was also isolated in sufficient numbers from these field studies to be included in the SRD treatment and control indications.

The effectiveness of enrofloxacin for the control of colibacillosis associated with E. coli was evaluated in a multi-site natural infection field study. At each site, when at least 5% of the pigs were defined as "clinically affected" (presence of diarrhea and either depression or gauntness), all pigs were administered enrofloxacin as a single IMdose of 7.5 mg/kg BW or an equivalent dose volume of saline. At 7 days post-treatment, the success rate was statistically significantly higher (P = 0.0350) in the enrofloxacin-treated group (61.5%) compared with the saline-treated group (44.7%).

The effectiveness of enrofloxacin administered as a single IM doseof 7.5 mg/kg BW for the treatment and control of SRD or as a single SC dose of 7.5 mg/kg BW for the control of colibacillosis was confirmed by demonstrating comparable serum enrofloxacin concentrations following IM or SC injection into the neck of healthy male and female pigs.

# TOXICOLOGY:

The oral LD50 for laboratory rats was greater than 5000 mg/kg of body weight. Ninetyday feeding studies in dogs and rats revealed no observable adverse effects at treatment rates of 3 and 40 mg/kg respectively. Chronic studies in rats and mice revealed no observable adverse effects at 5.3 and 323 mg/kg respectively. There was no evidence of carcinogenic effect in laboratory animal models. A two-generation rat reproduction study revealed no effect with 10 mg/kg treatments. No teratogenic effects were observed in rabbits at doses of 25 mg/kg or in rats at 50 mg/kg.

# ANIMAL SAFETY:

**Cattle:** Safety studies were conducted in feeder calves using single doses of 5, 15 and 25 mg/kg for 15 consecutive days and 50 mg/kg for 5 consecutive days. No clinical signs of toxicity were observed when a dose of 5 mg/kg was administered for 15 days. Clinical signs of depression, incoordination and muscle fasciculation were observed in calves when doses of 15 or 25 mg/kg were administered for 10 to 15 days. Clinical signs of depression, inappetance and incoordination were observed when a dose of 50 mg/kg was administered for 3 days. No drug-related abnormalities in clinical pathology parameters were identified. No articular cartilage lesions were observed after examination of stifle joints from animals administered 25 mg/kg for 15 days. A safety study was conducted in 23-day-old calves using doses of 5, 15 and 25 mg/kg for 15 consecutive days. No clinical signs of toxicity or changes in clinical pathology parameters were observed. No articular cartilage lesions were observed in the stifle joints at any dose level at 2 days and 9 days following 15 days of drug administration. An injection site study conducted in feeder calves demonstrated that the formulation may induce a transient reaction in the subcutaneous tissue and underlying muscle. No painful responses to administration were observed.

**Swine: Subcutaneous Safety:** A safety study was conducted in 32 pigs weighing approximately 57 kg (125 lb) using single doses of 5, 15 or 25 mg/kg daily for 15 consecutive days. Incidental lameness of short duration was observed in all groups,

including the saline-treated controls. Musculoskeletal sti ness was observed following the 15 and 25 mg/kg treatments with clinical signs appearing during the second week of treatment. Clinical signs of lameness improved after treatment ceased and most animals were clinically normal at necropsy.

A second study was conducted in two pigs weighing approximately 23 kg (50 lb), treated with 50 mg/kg for 5 consecutive days. There were no clinical signs of toxicity or pathological changes. An injection site study conducted in pigs demonstrated that the formulation may induce a transient reaction in the subcutaneous tissue. No painful responses to administration were observed.

**Intramuscular Safety:** A safety study was conducted in 48 weaned, 20- to 22-day-old pigs. Pigs were administered enrofloxacin, at 7.5, 22.5 and 37.5 mg/kg BW by IM injection into the neck once weekly for 3 consecutive weeks. All pigs remained clinically normal throughout the study. Transient decreases in feed and water consumption were observed after each treatment. Mild, transient, post-treatment injection site swellings were observed in pigs receiving the 37.5 mg/kg BW dose. Injection site inflammation was found on post-mortem examination in all enrofloxacin-treated groups.

### **STORAGE CONDITIONS:**

Protect from direct sunlight. Do not refrigerate or freeze. Store at 20-30°C (68-86°F), excursions permitted between 15°C (59°F) to 40°C (104°F). Precipitation may occur due to cold temperature. To redissolve, warm and then shake the vial.

#### HOW SUPPLIED

Tenotryl<sup>™</sup> (enrofloxacin) Injectable Solution:

100 mg/mL 100 mL Bottle

100 mg/mL 250 mL Bottle

100 mg/mL 500 mL Bottle

#### **REFERENCES:**

1. Hooper, D. C., Wolfson, J. S., Quinolone Antimicrobial Agents, 2nd ed,59 - 75, 1993.

To report suspected adverse drug events, for technical assistance orto obtain a copy of the Safety Data Sheet, call 1-800-338-3659.

Virbac AH, Inc.

PO Box 162059

Fort Worth, TX 76161

Rev. 12/21

Approved by FDA under ANADA # 200-688

TENOTRYL is a trademark of Virbac S.A.

#### Virbac

# Tenotryl<sup>™</sup> (enrofloxacin) 100 mg/mL Antimicrobial Injectable Solution

DOSAGE AND ADMINISTRATION:

Cattle

sangle-Dose Therapy (BRD Treatment): Administer, by subcutaneous injection, a single dose of 7.5-12.5 mg/kg of body weight (3.45.7 mL/100 k). Mg/biole. The Therapy Content of the State of

body weight (2 4 5.7 mL) 700 lb). Multiple-Day Thesayey (BPD Treatment): Administer daily, a subcuranceus de of 25.5 mg/kg of body weight (1.1-2.3 mL, 7/100 lb). Treatment should be repeated at 24-hour intervals for three days. Addisonal treatments may be given on Days 4 and 5 to animals that have shown clinical improvement but not total recovery.

Single-Dose Therapy (BRD Control): Administer, by subcuta injection, a single dose of 7.5 mg/kg of body weight (3.4 mL/100 lb). See insert for examples of conditions that contribute to high risk. Administered dose volume should not exceed 20 mL per injection site.

Swine: Administer, either by intramuscular or subcutareous (behind the ear) imection, a single dose of 7.5 mg/kg of body weight (3.4 mL/100 b). Administered dose volume should not exceed 5 mL per injection should be infrasted within the first 60 days aummetration snous the inflated within the first 60 days post-wearing when clinical signs are present in at least 2% of the animals in the group. See package insert for full docage an administration information.

Manufactured for: Virbac AH, Inc. PO Box 162059 Fort Worth, TX 76161 1-800-338-3659

us virbac o

TENOTRYL is a trademark of Virbac S.A. 66716-01

Virbac

#### Tenotryl<sup>™</sup> (enrofloxacin) 100 mg/mL Antimicrobial

Injectable Solution

#### DOSAGE AND ADMINISTRATION:

cause: Single-Dose Therapy (BRD Treatment): Administer, by suboutaneous injection, a single dose of 7.5-12.5 mg/kg of body weight (3.4-5.7 mL/100 lb). body weight (2.4.5.7 mL/100 h). Multiple-tay Theory (BRD Treatment) - Administre duily, a subcuttence-off one of 2.5.4 mg/sq of body weight (1.1.4.2 mL/100 h). Treatment - Administre duily, a subcuttence-off one of 2.5.4 mg/sq of body weight (2.4.4 mg/

#### Saine

Administer, either by intramuscular or subcutaneous (behind Administre, either by intransuration or subcataneous (behind the ear) injection, a single dieso of 75 mg/lag of body weight (3.4 mL/100 b), Administred dasse volume should not association for the primetion site. For the control of colloadilosis, administration should be initiated within the first 60 days post-weaking when clinical signs are present in at least 2% of the animals in the spray. See package insert for full dosage and administrations information.

Manufactured for Nanufactured for: Virbac AH, Inc. PO Box 162059 Fisit Worth, TX 76161 1-800-338-3659 us.virbac.com

TENOTRYL is a trademark of Virbac S.A. 66717 - 01



INVECTIONS: Carlie: Teroty "In is indicated in beef and non-lactating dairy cattle for: Single Date: The says: the treatment of burier expiratory desires (BRD), associated with Matchenian Lawnovich: Partawalda multicoda inistightika scensi and Mangalaema boxis in beef and non-lactating dairy cattle; and for the construl of BRD in moles and non-lactating dairy cattle at high into d developing BRD associated with M. haemolynica, P. multicoda and Miniple-Day Theory: the treatment of buries respiratory disease (BRD) associated with Matchenian haemolytica; Partawala multicoda and highpublics scensi (BRD) associated with M. haemolytica; P. multicoda and histophilas scensi (BRD) associated with A chandbacking beginspreamanae, Pastewalia multicoda; Asemolytica; Pastewala and control of swine imparatory disease (BRD) associated with A chandbacking beginspreamanae, Pastewalia multicoda; Asemolytica; Pastewalia and control of swine imparatory disease (BRD) associated with A chandbacking beginspreamanae, Pastewalia multicoda; Asemolytica; Pastewalia and control of swine imparatory disease (BRD) associates the dispersion associated with Actinobacking beginspreamanae, Pastewalia multicoda; Asemolytica; Pastewalia and control of collacalitosis in groups or press of wanned gas where collacalitosis associated with Actinohica on the second of collacalitosis in groups of press of wanned gas where collacalitosis associated with a terror of the top see dispersion. Torgenize base 200 mg m, in hulty ladobal do mg benytic base diagoments. The control of second is of the pasteria torgenize and pasteria control of spine expension water to rejection q.s. Lise within 30 spine of the paneture and paneture a maximum of 20 times with a 15-page needle or stanker, or 4 times with a 4 dave off spike 4.75 rmm canadis. Approache: remaining bepond these parameters should be discated.

#### RESIDUE WARNINGS:

RESIDUE WARNINGS: Cattle, Animals intended for human consumption must not be situathread within 28 days from the last treatment. This product is not approved for female days cattle 20 months of age or older, including dry days core. Use in threa cattler may cause drug residues in milk and/or in calters for to these cattler may cause drug period has not been established for this product in pre-unimating calves. Do not use in calves to be processed for well. Swine: Animals intended for human consumption must not be staughtered within 5 days of receiving a single-injection dose.

Supplement within 5 days of receiving a single-spectron dose. HUMAN WAINHORS: Net for use in humans. Reep out of reach of children. See package interf To opport supported alverse du up events, for tochnical assistance or to obtain a copy of the Safety Data Sheet, call - R80.338.359. For additional internation about advances duo a generineer reporting for aximal drugs, coretact FDA at 1-886-FDA-VEIS or MUL, Jaweuk Bag, overlast FDA at 1-886-FDA-VEIS or MUL, Jaweuk Bag, 2003 OC (68-667): exousionis permitted between 15/C (1977) E 40°C (1047): Precipitation may occur due to cold temperature. To redisolve, warm and then shake the val. Read package insert carefully for complete details.



Virbac

Tenotryl<sup>™</sup> (enrofloxacin) 100 mg/mL Antimicrobial Injectable Solution

For Subcutaneous Use In Beef Cattle And Non-Lactating Dairy Cattle For Intramuscular or Subcutaneous Use In Swine

Not For Use in Female Dairy Cattle 20 Months Of Age Or Older Or In Calves To Be Processed For Veal

CAUTION: Federal (USA) law restricts this drug to use by or on the

Galorismic Textus order of a licensed veterimarian. Federal (USA) law prohibits the extra-label use of this drug in food producing animals. To assure responsible antimicrobial drug use, entrafloacian should only be used as a second-live drug for oblacibloss in swine following consideration of other therapeutic options.



#### Tenotryl"

W

-	Treat	Control		
right lb)	Single-Dose Therapy 7.5 - 12.5 mg/kg Dose Volume (mL)	Multiple-Day Therapy 2.5 - 5.0 mg/kg Dose Volume (mL)	Single-Dose Therapy 7.5 mg/kg Dose Volume (mL)	
00	3.5 - 5.5	1.5-2.0	3.5	
00	7.0 - 11.0	2.5-4.5	7.0	
300	10.5 - 17.0	3.5-6.5	10.5	
100	14.0 - 22.5	4.5-9.0	14.0	
500	17.0 - 28.5	5.5 - 11.5	17.0	
500	20.5 - 34.0	7.0 - 13.5	20.5	
001	24.0 - 39.5	8.0 - 16.0	24.0	
300	27.5 - 45.5	9.0 - 18.0	27.5	
000	31.0 - 51.0	10.0 - 20.5	31.0	
000	34.0 - 57.0	11.0 - 23.0	34.0	
100	37.5 - 62.5	12.5-25.0	37.5	



Tenotryf\* tment Schedule for Cattle\*

Control

Dose and Tre

Treatment

INDICATIONS

ert

100 mL

250 ml

INDICATIONS Cattle: Terrotryl<sup>®</sup> in indicated in beef and non-lactating dairy cattle for: Single-Toos: Therapy: The treatment of hovine requiratory disease (IRSU associated with Mannhemin Internolytics, Patternella non-lactating dairy cattle; and for the control of 1810 in beef and non-lactating dairy cattle at high risk of dowloging IRSD associated with M. Hanovy/tice, P multicold, H: some and Morphisms and the observed Middge-Cuty Therapy: the treatment of bovine respiratory disease (IRFU) associated with Mannhemin Internolytics, Patternella nutlicolds and Histophellow Therapy: the treatment of bovine respiratory disease (IRFU) associated with Mannhemin Internolytics, Patternella nutlicolds and Histophellow Therapy: the treatment and control of neine reginatory disease (IRFU) associated with Attended with Attended planoproxemonia; Patternella methicids, Homophella parasas; Streptococcut sin; Bendred not with Attended and Myrophorn Myroperennomia. The control of collabacities is in groups at pent of warmed pay where collabacities associated with Exclusion collabors.

been diagnosed. CONTAINS PER nd.: Enroficeacin 100 mg. Excipients: L-arginine base 200 mg. e-butpl alcohol 30 mg. berzyl alcohol (as a preservative) 20 mg and water for injection q.s.

Use within 30 days of first puncture and puncture a maximum of 30 times with a 16 gauge needle or smaller, or 4 times with a draw-aff spike 4.75 mm or smaller. Any product remaining beyond these parameters should be discussed.

acade. BESIDE WARNINGS: Cattle: Annabi intended for human consumption must not be sharpforeed within 28 days from the last treatment. This product is not a papeved for female daisy cattle? 20 month of algo er older, including dry dairy cows. Use in these cattle may cause daug period has not been established for this product is pre-runnianting adves. Die not use in calves ho be processed for val. Swine, Annabi intended for human scoreamption must not be slaughtered within 5 days of receiving a single-injection dose.

HUMAN WARNINGS: Not for use in humans. Keep out of reach of

children. See package insert To report suspected adverse drug events, for technical assistant to obtain a copy of the Safety Data Sheet, call 1-800-338-3659. intance or to obtain a copy or ten anny data server, can r-seco-additional for additional information about adverse drug experience reporting for animal drugs, context FDA at 1-88+FDA-VETS or MTU, Jowen Kilo, govinyost tainanalae. STORAGE COMDITIONS: Protect from direct sunlight. Do not refrigerate

of these. Store at 20-30°C (68-86°F), executions permitted between 15°C (59°F) to 40°C (104°F). Precipitation may occur due to cold temperature. To redissolve, warm and thes shake the vial. Read package insert carefully for complete details.



Tenotryl<sup>™</sup> (enrofloxacin)

100 mg/mL Antimicrobial

Injectable Solution

Approved by FDA under ANADA # 200-688

Multiple-Day Therapy 2.5 - 5.0 mg/kg Dose Volume (ml.) Single-Done Therapy Single-Dase Therapy 7.5 mg/kg rse Valume (n 7.5 - 12.5 mg/kg lose Volume (mL) (b) 100 200 300 400 15-20 25-45 35-65 45-90 55-115 70-125 3.5 - 5.5 7.0 - 11.0 7.0-11.0 10.5-17.0 14.0-22.5 17.0-28.5 20.5-24.0 24.0-38.5 27.5-45.5 31.0-51.0 34.0-57.0 37.5-62.5 mes have been ro ini the dose range 10. 14. 500 600 20.5 700 8.0-16.0 800 900 1000 1100 9.0-18.0 10.0-20.5 11.0-23.0 12.5-25.0 27 31 34.0 37.5 Tenotryf Dose Schedule for Swine Weight (Ib) Dose Vol ne (mL) 100



with

250 mL



enrofloxacin solution	on					
Product Information						
Product Type		PRESCRIPTION ANIMAL DRUG	ltem	Code (Source)	NDC:51312	1-027
Route of Adminis	tration	SUBCUTANEOUS, INTRAMUSCULAR				
Activo Ingradio	nt/Activo	Majaty				
Active Ingredie	nt/Active	Molety				
Ingredient Name Basis of Strength Strength						gth
ENROFLOXACIN (UNII: 3DX3XEK1BN) (ENROFLOXACIN - UNII:3DX3XEK1BN)		) ENF	ROFLOXACIN	100 mg in	ո 1 mL	
Product Characteristics						
Color	yellow (clear yellowish solution)			Score		
Shape	e Size					
Flavor				Imprint Code		
Contains						

Packaging						
#	Item Code	Package Description	Marketing Start Date	Marketing End Date		
1	NDC:51311-027-10	100 mL in 1 VIAL, MULTI-DOSE				
2	NDC:51311-027-25	250 mL in 1 VIAL, MULTI-DOSE				
3	NDC:51311-027-50	500 mL in 1 VIAL, MULTI-DOSE				

Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
ANADA	ANADA200688	06/30/2022		

Labeler - Virbac AH, Inc. (131568396)

# Registrant - Virbac AH, Inc. (131568396)

Revised: 7/2022

Virbac AH, Inc.